Evidence map›Paper›PMID 40255738›Full record

ReviewCureus2025

Ginger: A Nutraceutical Supplement for Protection Against Various Cardiovascular Diseases in Clinical Trials.

Taherah Mohammadabadi, Aimen E Ben Ayad, Akhil Maheshwari

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taherah MohammadabadiFaculty of Animal Science and Food Technology, Agricultural Sciences and Natural Resources University, Mollasani, IRN.
Aimen E Ben AyadDepartment of Pediatrics/Neonatology, Tawam Hospital, Al Ain, ARE.
Akhil MaheshwariDepartment of Neonatology/Pediatrics, Boston Children's Health Physicians/New York Medical College, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) are increasing in prevalence, causing significant health issues and remaining one of the leading causes of death worldwide. Medical herbs continue to be used as an alternative treatment approach for several diseases, including various CVDs. Since ancient times, certain herbs have been safely used to alleviate the risk of developing CVD and control or improve the symptoms of medical conditions, such as in cases of congestive heart failure, angina, atherosclerosis, and systolic hypertension. Ginger is one of the medicinal herbs that neutral agents use to prevent and treat various CVDs. Ginger has antioxidant, anti-inflammatory, and immunomodulatory components and may improve cardiovascular risk factors. The natural components of ginger effectively inhibit inflammation, oxidative stress, and insulin resistance; may reduce fasting blood glucose, triglyceride, and low-density lipoprotein (LDL) levels; and prevent CVDs. Ginger can be an alternative that has lower side effects. Ginger's bioactive components may improve human blood lipid profile and decrease blood sugar levels. Further research is necessary to confirm ginger phytochemicals' efficacy and mechanism for various CVDs. The present review aims to summarize the effects of ginger's bioactive compounds on cardiovascular diseases.

Indexed as

atherosclerosisgingergingerolshyperlipidemiahypertensionnutraceuticalphytochemical

Identifiers

PMID40255738
PMCPMC12007927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.